Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue after high-dose methotrexate in osteosarcoma for the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Isofol Medical AB, a clinical stage oncology company, announces the release of an abstract from a retrospective study that will be presented at the ASCO Annual Meeting, which will be held June 2–6, 2017, in Chicago.
Poster Session: Sarcoma; Sunday, June 4, 08:00-11:30 a.m. CDT, Hall A, Poster Board #351
Authors Mikael Eriksson, Karin Ganlöv and Louise Kvistgaard will be present during the poster session.
Citation: J Clin Oncol 35, 2017 (suppl; abstr 11028)
For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
Phone: +46 (0)707 646 500
Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert it’s effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in two clinical Phase II studies.
About Isofol Medical AB
Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the NASDAQ First North Premier. Certified Adviser is FNCA Sweden AB